Opendata, web and dolomites

ESCulab SIGNED

European Screening Centre; Unique Library for Attractive Biology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ESCulab" data sheet

The following table provides information about the project.

Coordinator
STICHTING LYGATURE 

Organization address
address: JAARBEURSPLEIN 6
city: UTRECHT
postcode: 3521 AL
website: http://www.lygature.org/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 36˙729˙319 €
 EC max contribution 18˙249˙992 € (50%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-12-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2023-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING LYGATURE NL (UTRECHT) coordinator 1˙434˙943.00
2    PIVOT PARK SCREENING CENTRE BV NL (OSS) participant 7˙128˙756.00
3    BIOASCENT DISCOVERY LIMITED UK (NEWHOUSE) participant 6˙475˙450.00
4    UNIVERSITY OF DUNDEE UK (DUNDEE) participant 1˙256˙612.00
5    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 491˙230.00
6    EDELRIS SAS FR (LYON) participant 292˙600.00
7    SYGNATURE DISCOVERY LIMITED UK (NOTTINGHAM) participant 292˙600.00
8    SYNCOM BV NL (GRONINGEN) participant 292˙600.00
9    TAROS CHEMICALS GMBH & CO KG DE (Dortmund) participant 292˙600.00
10    MERCATORIAL BV NL (NIJMEGEN) participant 265˙243.00
11    MERCALEADS BV NL (NIJMEGEN) participant 27˙356.00
12    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
13    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
14    GRUNENTHAL GMBH DE (AACHEN) participant 0.00
15    INSTITUT DE RECHERCHES SERVIER FR (SURESNES) participant 0.00
16    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
17    Medicines for Malaria Venture CH (GENEVE) participant 0.00
18    MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN DE (DARMSTADT) participant 0.00
19    SANOFI-AVENTIS DEUTSCHLAND GMBH DE (FRANKFURT AM MAIN) participant 0.00
20    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific insights into innovative drug starting points. New biological ideas will be collected by crowdsourcing, novel targets, phenotypes and pathways translated and de-risked by delivering high-quality chemical starting points for drug development. Innovators from EU academics and SMEs are offered access to state-of-the-art industry-grade facilities, drug discovery expertise, and a top-quality, curated library with over 550,000 unique compounds suitable for screening potential drug targets. The ESCulab drug discovery data generated will allow the innovators to build a proposition that is likely to attract investors and/or drug developers and stimulate them to further exploit these findings. Ultimately, this will result in novel medicines – based on basic scientific findings – that will help patients (sooner).

ESCulab will achieve this by starting off the shoulders of the European Lead Factory (ELF), where this principle has been successfully implemented. 15 out of the 18 ESCulab consortium members were involved in ELF, thus ensuring maximum benefit from the ELF legacy. ESCulab will expand and enhance ELF by supporting 185 new screens. Important additions include the application of a much larger compound collection for screening, the ability to accommodate the more complex phenotypic screening assays, and the building of a sustainable business model to ensure access to Collaborative Drug Discovery activities beyond the funding period. The delivery of qualified hit lists (QHLs) is the end point for this project, but during the funding period, ESCulab will attract additonal funding for externally paid screens and hit-to-lead projects for organizations such as charities and foundations for long term sustainability of the initiative.

 Deliverables

List of deliverables.
Report on the establishment of an Ethics Advisory Board Documents, reports 2020-04-02 08:51:33
Report on the establishment of a secure IT platform for sharing project documents Documents, reports 2020-03-27 11:47:40
Report on delivery of 1st screening sets to all 10 screening centres Documents, reports 2020-03-27 11:45:30
Report on the establishment of a Legal and IP committee Documents, reports 2020-03-27 11:47:33
Report on the HDB implementation for HCS Documents, reports 2020-03-27 11:47:49
Report on established Sharepoint environment for secure data sharing outside the HDB Documents, reports 2020-03-27 11:47:57
Report on application process being operational Documents, reports 2020-03-27 11:47:14
Annual update on communication and dissemination activities (1) Documents, reports 2020-03-27 11:45:49
Annual report on recruitment activities and number of submitted proposals (1) Documents, reports 2020-03-27 11:45:06
Annual report on project output and post-QHL processes (1) Documents, reports 2020-03-27 11:46:30
Project website established Websites, patent fillings, videos etc. 2020-03-27 11:46:36
Report on the HDB implementation for HTS at all ESCulab screening centres Documents, reports 2020-03-27 11:44:57
Report on the created communication and recruitment material Documents, reports 2020-03-27 11:46:20
Annual update on the programme portfolio statistics (1) Documents, reports 2020-03-27 11:46:07
Report on implementation of recruitment plan at 3 regional/national life science organizations Documents, reports 2020-03-27 11:45:22

Take a look to the deliverables list in detail:  detailed list of ESCulab deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ESCULAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ESCULAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More